摘要
成纤维细胞生长因子21（fibroblast growth factor 21,FGF21）作为一种不依赖胰岛素的血糖调节因子,目前已被看做是治疗2型糖尿病的一个潜在的新型治疗因素.大量鼠类及灵长类动物模型的实验结果显示：FGF21可通过作用于脂肪组织及胰腺来降低血糖和甘油三酯含量,从而预防饮食诱导的肥胖及胰岛素抵抗.此外,FGF21也被证明可作为一种主要的内源性调控子,在禁食和酮症时起着关键的调控作用.然而,一些临床观察实验的结果表明,临床观察实验与动物模型实验之间虽然具有一定的相似性,但也存在很多不同,因而目前FGF21在人体中的生理学作用仍不明确.
Fibroblast growth factor 21 （ FGF21 ） is a factor regulating blood glocose independently on insulin, thus considered as a novel putative therapeutic agent for type 2 diabetes. A large amount of data, obtained from murine models and non-human primates, have showed that FGF21 can lower blood glucose and triglyceride levels via its effects on adipose tissue and pancreas, protecting against diet-induced obesity （DIO） and insulin resistance. Furthermore, FGF21 has also been proposed to play an important role in physiological response to starvation and ketosis, as a major endocrine regulator. The results from clinical observational studies and animal models studies displayed some similarities, but also differences, thus making the physiological role of FGF21 in man still unclear.
出处
《医学分子生物学杂志》
CAS
CSCD
2010年第3期263-266,共4页
Journal of Medical Molecular Biology
